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Background: Cardiogenic shock refractory to conventional therapy has very high mortality near 90%, with currently limited therapeutic options. The 
aim of the study is to evaluate the clinical impact on in-hospital and mid follow-up survival using the ExtraCorporeal Membrane Oxygenation (ECMO) 
system as a life-saving measure.
Methods: We enrolled 36 patients with cardiogenic shock refractory to optimal conventional therapy (inotropes and intra-aortic-balloon-pump) 
treated with ECMO implantation between January 2009 to October 2011. Veno-arterial extracorporeal membrane oxygenation has been implanted 
either at bedside under local anesthesia or in operating room. Data on in-hospital survival and on 6-months follow-up were collected.
Results: The mean age of the population (24 male and 8 female) was 47 ± 16 years, all patients presented with cardiogenic shock refractory to 
medical therapy due to different etiology (11/36 dilated cardiomyopathy, 18/36 ischemic cardiac disease, 3/36 myocarditis and 4/36 pulmonary 
embolism). Veno-arterial extracorporeal membrane oxygenation was implanted at bedside under local anesthesia in 22 awake patients (61%) and 
in the operating room in the remaining 14 (39%). Average duration of ECMO support was 11.4 ± 10 days (range 1-46). ECMO was used as bridge to 
transplantation in 10 patients (34%), bridge to recovery in 10 patients (34%) and bridge to bridge in 9 patients (32%). Seven patients (19%) died 
during ECMO support. Thirty-day overall survival after ECMO removal was 75.8% (22/29 pts). Eighteen patients (50%) were discharged from the 
hospital, with a 100% survival at six-months follow-up.
Conclusions: In our experience the use of ECMO as an additional treatment significantly improved the outcome of cardiogenic shock patients, 
greatly reducing the expected mortality both in-hospital and on 6-months follow-up, compared with current data available by the Literature.
